Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
6.12M
-
Shares change
-
-396K
-
Total reported value, excl. options
-
$68M
-
Value change
-
-$4.5M
-
Put/Call ratio
-
1.36
-
Number of buys
-
31
-
Number of sells
-
-20
-
Price
-
$11.11
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2015
65 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2015.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.12M shares
of 236M outstanding shares and own 2.59% of the company stock.
Largest 10 shareholders include Novo A/S (1.52M shares), EAGLE ASSET MANAGEMENT INC (1.24M shares), FMR LLC (724K shares), HealthCor Management, L.P. (595K shares), BlackRock Fund Advisors (474K shares), VANGUARD GROUP INC (288K shares), BALYASNY ASSET MANAGEMENT LLC (139K shares), STATE STREET CORP (103K shares), Cormorant Asset Management, LLC (100K shares), and Fort Washington Investment Advisors Inc /OH/ (94K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.